Article
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Gastroenterology - 1 Jan 2015
Curry Michael P, Forns Xavier, Chung Raymond T, Terrault Norah A, Brown Robert, Fenkel Jonathan M, Gordon Fredric, O'Leary Jacqueline, Kuo Alexander, Schiano Thomas, Everson Gregory, Schiff Eugene, Befeler Alex, Gane Edward, Saab Sammy, McHutchison John G, Subramanian G Mani, Symonds William T, Denning Jill, McNair Lindsay, Arterburn Sarah, Svarovskaia Evguenia, Moonka Dilip, Afdhal Nezam
Abstract excerpt
BACKGROUND & AIMS: Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence, but existing interferon-based regimens are poorly tolerated and are either ineffective or contraindicated in most patients. We performed a trial to determine whether sofosbuvir and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.